ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025
Retinoic acid-inducible gene-I aggravates neuroinflammation in early brain injury after subarachnoid hemorrhage through mediating brain microvascular endothelial cell pyroptosis.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Meningeal lymphatic dysfunction drives cognitive impairment after experimental subarachnoid hemorrhage.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Retinoic acid-inducible gene-I (RIG-I) is an immune signal that promotes inflammatory responses and plays an important role in endothelial cell-mediated inflammation. Currently, no studies have investigated the role of RIG-I in early brain injury (EBI) after subarachnoid hemorrhage (SAH). In this research, an in vivo SAH model was established in Sprague Dawley (SD) rats through carotid artery puncture, while oxyhemoglobin (OxyHb) was used to stimulate brain microvascular endothelial cells (BMVECs) to generate an in vitro SAH model. The results showed that RIG-I was activated and expressed in BMVECs in both in vivo and in vitro. To explore how RIG-I is involved in the EBI, small interfering RNA was used to downregulate its expression. Compared with SAH rats, RIG-I knockdown rats had better short-term and long-term neurological recovery after SAH, milder brain edema and neurodegeneration, and weaker blood-brain barrier disruption and neuroinflammation. Furthermore, RIG-I knockdown attenuated SAH-induced BMVECs pyroptosis. In OxyHb-stimulated BMVECs, RIG-I knockdown reduced the cellular dysfunction and inflammation. To determine the mechanism of RIG-I in BMVECs pyroptosis, co-immunoprecipitation was used to verify the direct binding of RIG-I to caspase-1, and RIG-I knockdown could reduce Oxy-Hb-induced BMVECs pyroptosis, while caspase-1 inhibitor VX-765 can alleviate the tight junction loss, inflammation and pyroptosis exacerbated by RIG-I agonist. In addition, RIG-I levels in the cerebrospinal fluid of SAH patients were higher than those in controls and correlated with the levels of pyroptosis, inflammatory factors and clinical outcomes. In summary, the results demonstrated that RIG-I aggravates neuroinflammation after SAH by promoting caspase-1-mediated BMVECs pyroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.